Morphine pharmacokinetics in early infancy

Area of Science:

• Pharmacology
• Neonatal Medicine
• Clinical Pharmacy

Background:

• Morphine is commonly used for pain management in neonates.
• Understanding morphine pharmacokinetics in infants is crucial for safe and effective dosing.
• Infants, especially neonates, exhibit unique physiological differences affecting drug metabolism.

Purpose of the Study:

• To determine the pharmacokinetics of morphine in infants up to 10 weeks of age.
• To compare morphine elimination half-life and clearance between neonatal and older infant groups.
• To correlate pharmacokinetic parameters with observed duration of action and potential side effects.

Main Methods:

• Ten infants under 10 weeks of age receiving continuous morphine infusions were studied.
• Pharmacokinetic parameters, including elimination half-life and clearance, were measured.
• Infants were categorized into two groups: newborns (1-4 days) and older infants (5-10 weeks).

Main Results:

• Newborns (1-4 days) had a significantly longer elimination half-life (6.8 h) compared to older infants (3.9 h).
• Clearance in newborns was less than half that of older infants (6.3 ml x min-1 x kg-1 vs. 23.8 ml x min-1 x kg-1).
• These pharmacokinetic differences suggest a prolonged duration of action for morphine in very young infants.

Conclusions:

• Lower clearance and longer elimination half-life in newborns contribute to a prolonged morphine effect.
• The findings highlight the need for adjusted morphine dosing strategies in neonatal populations.
• Further research is required to understand the persistent respiratory sensitivity observed in older infants despite improved pharmacokinetic profiles.